Prosecution Insights
Prosecution Insights
Tech Center 3600 • Art Units: 1653 1655 1657 1783 3628
This examiner grants 50% of resolved cases
Vera Afremova has 881 resolved cases in Art Unit 1653 of Tech Center 3600. The allowance rate for these cases is 50.5%, and the median days to allowance is 1319. These 881 cases provide a substantial data set for evaluating the examiner's prosecution style.
The interview lift of 29.1% is a key figure for practitioners. This lift indicates that an interview can notably increase the probability of allowance compared to the 50.5% baseline rate. Given the 1319-day median pendency, an interview may be an effective way to move cases toward a resolution.
In Tech Center 3600, the 29.1% interview lift offers a strategic advantage. Practitioners should consider this lift alongside the 50.5% allowance rate and the 1319-day median timeline. These metrics from 881 resolved cases help to set expectations for applications in Art Unit 1653.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18905553 | COMPOSITION FOR IMPROVING SKIN CONDITION | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18991944 | SYSTEM FOR PROVIDING CELL PRODUCT | Non-Final OA | FUJIFILM Corporation |
| 18776013 | Pharmaceutical composition for antibacterial wound healing comprising chia seeds and biodegradable materials | Final Rejection | UIF (University Industry Foundation), Yonsei University |
| 17172528 | CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION | Non-Final OA | GENENTECH, INC. |
| 18714481 | DEVELOPMENT OF FOOD-GRADE FUNGAL FERMENTATES WITH ANTIMICROBIAL ACTIVITY AND THE USE THEREOF | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18838938 | SINGLE CELL PROTEIN PRODUCTS | Non-Final OA | DSM IP ASSETS B.V. |
| 17801002 | METHODS FOR REHABILITATING HEART FAILURE USING GENE THERAPY | Final Rejection | UNIVERSITY OF UTAH RESEARCH FOUNDATION |
| 19067759 | NOVEL METHOD TO ALTER THE PROTEOME OF A DISEASED HEART BY INJECTION OF ECM PARTICLES PRODUCED FROM DECELLULARIZED 3D MICROTISSUES OF HUMAN MESENCHYMAL STEM CELLS | Non-Final OA | XM Therapeutics, Inc. |
| 18713320 | FAT AND WAX MICROENCAPSULATED AMBIENT STABLE BACTERIA AND PROBIOTICS | Non-Final OA | Chr. Hansen A/S |
| 18713313 | COMPOSITIONS FOR INCREASED STABITLITY OF BACTERIA | Non-Final OA | Chr. Hansen A/S |
| 18642656 | GROWTH MEDIA COMPOSITIONS AND GROWTH ENVIRONMENTAL CONDITIONS FOR IMPROVED AERIAL MYCELIUM | Non-Final OA | Ecovative LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy